Business development

Biomay has entered into partnerships with several leading players in the field of allergy immunotherapy and diagnostics based on its first and second generation recombinant allergens.

Biomay is interested in entering into discussions with pharmaceutical companies for licensing and/or co-development of its innovative pipeline candidates. Preferably we will enter into such partnerships following successful clinical proof of concept.

This pertains especially to our lead product BM32, for which we now have successfully completed the phase II  clinical trial program in grass pollen allergic patients. This exciting product is now ready for phase III development.

We are always interested in discussions with companies developing gene and cell therapy products. We can offer high quality GMP manufacturing of plasmid DNA for products in this area. We strongly believe that we can offer highly competitive conditions for a collaboration.